Dr. Christopher Hentschel

Ulysses Advisory Group

Best Practices: Entrepreneurial Ecosystems around the World

Ulysses Advisory Group

Basic Research Translational Research Product Development

Public-Private Ecosystems Optimize Healthcare R&D

Image here. Always this height, but width can vary

Neither the public nor theprivate sectors alone canDeliver optimal healthcareR&D.

But together there is thepotential for enormoussynergy and progress.

Examples 1: MRC , London UK;Example 2: MMV, Geneva (backup)

Public Goods Common Goods Private Goods

Ulysses Advisory Group

Public-Private Partnerships Optimize R&D productivity, particularly where incentives are needed

for the private sector to engage

Universities >>>> PPPs >>>>>> Industry PPPs help mitigate the ‘Valley of Death’ Phenomenon

• Rickets caused by lack of vitamin D (1916) • Discovery and development of penicillin (1940s)• Pioneered randomised controlled trial design (1940s)• Structure of DNA (1950s)• Discovery of link between smoking and cancer (1950s)• Clinical trials for radiotherapy for cancer (1960s)• Chemotherapy for leukaemia and monoclonal antibodies (1970s)• Invention of DNA fingerprinting (1980s)• Gene for Huntington’s disease discovered (1990s)• Humanised therapeutic antibodies in widespread use (2000s)• 22 Nobel prizes have been awarded to MRC-supported scientists• MRC Collaborative Centre (1987) > MRCT + MVM (2000 – Present)

MRC discoveries and developments Ulysses Advisory Group

Ulysses Advisory Group

NIMR 1913 – 2013 Francis Crick Institute (2016)

Ulysses Advisory Group

Translation of basic research takes time 1973: Mouse monoclonal antibodies isolated by César Milstein 1986: Michael Neuberger and Greg Winter ‘humanise’ mouse

antibodies and develops and the technology for producing antibodies in vitro

2003: MRC-developed Humira® licensed to treat arthritis 2008: 21 monoclonal antibody drugs on market for treating

breast cancer, leukaemia, asthma, arthritis, psoriasis and transplant rejection

2011: Antibodies make up 1/3 of new drugs for cancer, arthritis and asthma; global antibody market estimated to be worth $50bn

2016: Bio-similars market developing in emerging economies

Ulysses Advisory Group

MRC exploitation results since 1987• 92 new products and interventions launched, including several

‘blockbusters’.• Creation of 104 companies, 56 formed since 2006.• 578 patents granted since 2006, with around 30% licensed with

royalty income >$250m since 2006• More than 100 new industry collaborations are reported every

year• Lead partner in the new European Innovative Medicines Initiative

Ulysses Advisory Group

The European Union and the

pharmaceutical industry

have joined forces to make

drug R&D processes in Europe more

innovative and efficient,

enhance Europe’s competitiveness

& address key societal challenges

by forming

the biggest PPP in Life Science

8

EU Innovative Medicines Initiative:

Ulysses Advisory Group

Total IMI SME participants by countryUnited KingdomGermanyFranceBelgiumNetherlandsIcelandSpainDenmarkFinlandHungarySwedenItalyAustriaIrelandIsraelGreecePortugalSwitzerland

Ulysses Advisory Group Thank You For Your Attention

Confidential 10

For more information see ulyssesadvisorygroup.com

Ulysses Advisory Group

Backup Slides: MMV Geneva

Confidential 12

For more information see ulyssesadvisorygroup.com

Ulysses Advisory Group

MMV’s mission

“Medicines for Malaria Venture is a not-for-profit foundation dedicated to reducing the burden of malaria

in disease endemic countries by discovering, developing and delivering

new affordable antimalarials through effective public-private partnerships.”

MMV’s global network of R&D

GSK

=Pharmaceutical partners

=Universities/Institutes

=National Research Institutes

=National Agency

=International Agency

Swiss Tropical Institute

National Science & Technology Development Agency

GSK

University of California, San Francisco

Texas A&M

Jacobus

Albert Einstein College of Medicine

Howard Hughes Medical Institute

University of Mississippi

Gadjah MadaUniversity

University of Maryland

University of Washington Yale UniversityBMS

ImmtechInt’l

University of North CarolinaGeorgia State University

Tulane University

Paratek

University of Nebraska

Monash University

Novartis

Roche

University of Liverpool

Ranbaxy

WRAIR

AFRIMS

Guangzhou University of Traditional Chinese Medicine

Holleykin

Mahidol UniversityUniversity of Oxford/WellcomeTrust (Thailand, Vietnam, Kenya)

Shin Poong

WHO/TDR

Bayer

University of Iowa

Hong Kong University of Science & Technology

DFID

+ =Clinical trial sites (under review)

++

+++

GSK

=Pharmaceutical partners

=Universities/Institutes

=National Research Institutes

=National Agency

=International Agency

Swiss Tropical Institute

National Science & Technology Development Agency

GSK

University of California, San Francisco

Texas A&M

Jacobus

Albert Einstein College of Medicine

Howard Hughes Medical Institute

University of Mississippi

Gadjah MadaUniversity

University of Maryland

University of Washington Yale UniversityBMS

ImmtechInt’l

University of North CarolinaGeorgia State University

Tulane University

Paratek

University of Nebraska

Monash University

Novartis

Roche

University of Liverpool

Ranbaxy

WRAIR

AFRIMS

Guangzhou University of Traditional Chinese Medicine

Holleykin

Mahidol UniversityUniversity of Oxford/WellcomeTrust (Thailand, Vietnam, Kenya)

Shin Poong

WHO/TDR

Bayer

University of Iowa

Hong Kong University of Science & Technology

DFID

+ =Clinical trial sites (under review)

++

+++

Ulysses Advisory Group

Example: MMV’s Synthetic Peroxide Project - an example of International Partnership

Project team: University of Nebraska

Swiss Tropical Institute

Monash University

Roche/Basilea

Ranbaxy Laboratories

+ Outsourced Support• Cideim • St George’s Hospital Medical

School • Quintiles • Pharmalytics • Inveresk • Unimark • RCC • Fulcrum • Basilea • Cerb • Cerep • Maccine• MDS• ICGEB

Ulysses Advisory Group

JointR&D

MMV Input•$$$ •Drug Profile•Background IPR•Link to WHO/Policy•Malaria Expertise

Pharma•Chemistry IPR•Toxicology•Know How•Assets in Kind•Technology

MMV Gets•Rights in DEC•IPR in ‘Field’•Drug Supply•Return on non DEC Sales

Pharma/Bio Gets•Rights in non DEC•IPR outside ‘Field’•PR Benefit•HR Benefit•Validation of Technology

Public

Private

Inputs and Outputs of Joint R&D